Showing 91-100 of 5234 results for "".
- Large Registries Leave Data Gaps for Melanoma in Black Patientshttps://practicaldermatology.com/news/large-registries-leave-gaps-in-data-on-melanoma-in-black-patients/2462232/New research published in JAMA Dermatology provides crucial patient-level and tumor-level insights into melanoma in Black patients that has been lacking in large registiries. The case series was conducted from January 2006 to October 2022 at two tertiary care centers (University of Texas Southwest…
- Guselkumab Demonstrates Significant and Rapid Scalp Psoriasis Clearance in People of Colorhttps://practicaldermatology.com/news/tremfya-guselkumab-demonstrates-significant-and-rapid-scalp-psoriasis-clearance-in-people-of-color-in-new-large-phase-3b-study/2462218/At the Maui Derm Hawaii 2024 conference, Johnson & Johnson presented topline data from Cohort B in the Phase 3b VISIBLE study that demonstrated that TREMFYA® (guselkumab) showed rapid and significant clearance in moderate to severe scalp psoriasis (PsO) and significant improvement in scalp itch, as…
- FDA Gives Nod to Marketing DermaSensor for Skin Lesion Evaluationhttps://practicaldermatology.com/news/fda-gives-nod-to-dermasensor-for-skin-lesion-evaluation/2462213/The U.S Food and Drug Administration (FDA) announced that it has granted authorization for marketing for the DermaSensor (DermaSensor Inc.) prescription device, indicated for the evaluation of skin lesions suggestive of melanoma, basal cell carcinoma, and/or squamous cell carcinoma in patients aged…
- Insufficient Disease Control in Moderate-to-Severe AD: Year-long Longitudinal Study Reveals Treatment Gapshttps://practicaldermatology.com/news/insufficient-disease-control-in-severe-atopic-dermatitis-a-12-month-longitudinal-study-reveals-treatment-gaps/2462212/A recent study presented at the Revolutionizing Atopic Dermatitis (RAD) Virtual Conference highlighted has shed light on the persistent issue of therapeutic inertia in the treatment of moderate-to-severe atopic dermatitis (AD), even with the advent of newer, advanced systemic therapies. Over a 12-m…
- Researchers ID Genetic Risk Factors for Early-Onset Merkel Cell Carcinomahttps://practicaldermatology.com/news/researchers-id-genetic-risk-factors-in-early-onset-mcc/2462201/New research indicates that germline variants in genes are significantly associated with early-onset Merkel cell carcinoma (MCC). The case-control study included 1,012 individuals (37 of whom had early-onset MCC, 45 with later-onset MCC, and 930 controls) who were prospectively enrolled in the st…
- Triple Combo Acne Gel Well-tolerated in Two Studieshttps://practicaldermatology.com/news/triple-combo-acne-gel-well-tolerated-in-phase-2-study/2462194/A triple combination acne gel (IDP-126) was shown to be safe and effective in two phase 3 studies, according to a new analysis. Researchers publishing in the Journal of the American Academy of Dermatology analyzed the results of two phase 3, double-blind, 12-week studies that randomized participan…
- Birch Triterpenes Topical Gel Gets FDA Approval for Treatment of Epidermolysis Bullosahttps://practicaldermatology.com/news/birch-triterpenes-topical-gel-gets-fda-approval-for-treatment-of-epidermolysis-bullosa/2462190/Chiesi Global Rare Diseases announced today that the FDA had approved FILSUVEZ® (birch triterpenes) topical gel for the treatment of junctional epidermolysis bullosa (JEB) and dystrophic epidermolysis bullosa (DEB) in patients 6 months or older. According to the manufacturer, this formulation is …
- Dial Gives Back to Teachers With DonorsChoose, TeacherListshttps://practicaldermatology.com/news/dial-gives-back-to-teachers-with-donorschoose-teacherlists/2462170/For the third consecutive year, Dial is partnering with DonorsChoose, an education-focused nonprofit that supports public schools. For Back-To-School season 2023, Dial made a $100,000 2x Match Offer donation to health and wellness projects at schools, which resulted in 947 funded projects, 639 sc…
- Shmuel Gov Named COO of Strata Skin Scienceshttps://practicaldermatology.com/news/shmuel-gov-named-coo-at-strata-skin-sciences/2462169/Shmuel Gov is the new Chief Operating Officer (COO) of STRATA Skin Sciences. The Company has also hired Dr. Amandeep Kaur as Vice President of Marketing and Business Growth. Mr. Gov brings more than 30 years of industry experience in medical device business, operations, and R&D and, most recently…
- Is Separating the Good Skin T Cells from the Bad Ones a Key to Treating Psoriasis and Vitiligo?https://practicaldermatology.com/news/is-separating-the-good-skin-t-cells-from-the-bad-ones-a-key-to-treating-psoriasis-and-vitiligo/2462162/New research highlights ways to remove immune cells that cause autoimmune skin diseases such as psoriasis and vitiligo without affecting protective cells that fight infection and cancer. Tissue-resident T cells or TRM cells fight infections and cancerous cells in the skin, but when they not contro…